ZFYVE27 Knockout cell line (LN-229)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ZFYVE27 (zinc finger FYVE-type containing 27) encodes a membrane-associated protein containing multiple transmembrane domains, a Rab11-binding domain, and a FYVE lipid-binding domain. The encoded protein has been reported to promote neurite formation, suggesting a role in membrane trafficking and neuronal morphology. ZFYVE27 is therefore relevant to studies of Rab11-dependent trafficking, membrane organization, and neurite development.

Established in 1979, LN-229 is a widely recognized and standard human glioblastoma cell line. The line was isolated from cells taken from a patient presenting with a malignant right frontal parieto-occipital glioblastoma (PubMed: 10416987). LN-229 cells adhere stably in culture, displaying an epithelial-like morphology, and are extensively utilized to study apoptotic pathways, cellular autophagy, and tumor suppressor gene interactions within neuro-oncology. Consequently, LN-229 serves as a premier and robust in vitro platform utilized globally for investigating glioblastoma multiforme (GBM) progression mechanisms, blood-brain barrier penetrating candidate drug screenings, and the evaluation of targeted therapeutic modalities.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.